← All CSP Flashcard Decks

Patient Adherence and Outcomes Flashcards

7 cards from real CSP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Patient Adherence and Outcomes flashcards as text
  1. A patient's fill history over a 180-day measurement period shows 150 unique days covered by medication. What is the proportion of days covered (PDC)?

    Answer: 0.83

    PDC equals days covered divided by days in the period, so 150/180 = 0.83.

  2. Why can the medication possession ratio (MPR) exceed 1.0 while PDC cannot?

    Answer: MPR sums days' supply without adjusting for overlapping fills

    MPR adds total days' supply dispensed, so early or overlapping refills can push it above 100%, whereas PDC counts each day only once.

  3. What PDC threshold is most commonly used by PQA and CMS Star Ratings to define a patient as adherent?

    Answer: 80%

    The Pharmacy Quality Alliance standard defines adherence as PDC of at least 80% for most chronic medication classes.

  4. A patient never picks up a newly prescribed biologic after the prescription is processed. This is best described as:

    Answer: Primary nonadherence

    Primary nonadherence occurs when a new prescription is never filled or never picked up.

  5. A patient stops taking an oral anticancer agent because she believes the nausea outweighs the benefit. This is classified as:

    Answer: Intentional nonadherence

    A deliberate decision to stop or alter therapy based on beliefs or side effects is intentional nonadherence.

  6. Which method is the most reliable way to confirm a patient understood injection instructions given during counseling?

    Answer: Ask the patient to explain and demonstrate the steps back (teach-back)

    Teach-back with return demonstration directly verifies comprehension and technique rather than assuming understanding.

  7. In specialty pharmacy, 'persistence' refers to:

    Answer: The duration from therapy initiation to discontinuation

    Persistence measures how long a patient continues therapy, typically ending when a permissible gap (e.g., 30–60 days) is exceeded.